Top 10 Evidence-Based Longevity Compounds Every Biohacker Should Know

Rapamycin (sirolimus) was discovered in a soil bacterium from Easter Island in the 1970s and entered medicine as an immunosuppressant for organ transplantation. Its longevity credentials emerged dramatically in 2009 when the Interventions Testing Program at the National Institute on Aging demonstrated that rapamycin extended lifespan in mice by 9–14% even when begun late in life — the equivalent of starting an intervention in 60-year-old humans. Since then, lifespan extension by rapamycin has been replicated across yeast, worms, flies, and mice, making it the most consistently validated pharmacological longevity intervention in biology. The mechanism centers on mTOR (mechanistic target of rapamycin), a master nutrient-sensing kinase that acts as a cellular growth-or-maintain switch. When nutrients are abundant, mTOR promotes protein synthesis, cell growth, and proliferation. When mTOR is inhibited — by caloric restriction, fasting, or rapamycin — cells shift into maintenance mode: autophagy is upregulated, protein quality control improves, and stem cell quiescence is better preserved. This broadly maps to at least four aging hallmarks: deregulated nutrient sensing, disabled macroautophagy, loss of proteostasis, and stem cell exhaustion. For healthy human longevity applications, the key question has been whether intermittent low-dose protocols could capture the benefits without the immunosuppressive side effects seen at transplant doses. The PEARL trial (PMC12074816) addressed this directly: 48 weeks of intermittent low-dose rapamycin in healthy older adults was safe, well-tolerated, and notably improved lean tissue mass in women. Blood panels, immune function, and infection rates showed no significant adverse deviations. Typical biohacker dosing is 5–10mg once weekly, often prescribed off-label by longevity physicians. Side effects at these doses include occasional mouth sores (aphthous ulcers), mild lipid changes, and transient glucose perturbations. The pharmacodynamic rationale for weekly dosing: full mTOR inhibition during the 24–48 hours post-dose, with recovery of mTORC2 (responsible for insulin signaling and immune function) between doses. This intermittent approach is specifically designed to capture autophagy and proteostasis benefits while minimizing immunosuppression.

Metformin has been prescribed to hundreds of millions of people for type 2 diabetes since the 1950s. Its safety profile — accumulated across seven decades of population-scale use — is exceptional. What the longevity field recognized in the 2010s is that metformin's benefits appear to extend well beyond glycemic control into a broad anti-aging profile that may be independent of diabetes status entirely. The primary mechanism is AMPK activation. Metformin inhibits mitochondrial Complex I, leading to a transient reduction in ATP production that activates AMP-activated protein kinase — the master metabolic regulator that acts as a cellular low-energy sensor. AMPK activation produces a cascade of longevity-relevant effects: inhibition of mTOR (shifting cells toward maintenance over growth), reduced IGF-1 signaling, decreased reactive oxygen species production, enhanced autophagy, and improved insulin sensitivity (PMC5943638). This mechanistic breadth — touching nutrient sensing, mitochondrial function, proteostasis, and inflammation — gives metformin a legitimately strong case as a geroprotective agent. The epidemiological evidence is striking. A large-scale analysis published in 2026 (PMC12223363) found that type 2 diabetic women taking metformin had a 30% lower all-cause mortality risk before age 90 compared to matched controls. Multiple studies have shown that metformin-treated diabetics outlive non-diabetic controls who are not on metformin — a finding so counterintuitive it catalyzed the TAME (Targeting Aging with Metformin) trial, the first FDA-approved trial with aging as a primary endpoint. TAME results are anticipated to be landmark. For healthy non-diabetic biohackers, the calculus is more nuanced. Metformin's AMPK activation partially overlaps with, and may blunt, the benefits of exercise-induced AMPK signaling. Research suggests co-administration with exercise programs may attenuate some cardiovascular adaptations. Thoughtful users cycle metformin on rest days or separate use from training windows. Standard longevity dosing is 500–1500mg/day; the Extended Release formulation (metformin ER) reduces gastrointestinal side effects that affect 30% of users on immediate-release formulations.

Cellular senescence is the state in which cells permanently exit the cell cycle following DNA damage, oncogenic stress, or other insults. Senescent cells are not benign: they resist apoptosis and secrete a complex pro-inflammatory cocktail — the senescence-associated secretory phenotype (SASP) — that includes IL-6, IL-1α, TNF-α, MMPs, and growth factors. SASP damages surrounding tissue, recruits immune cells, drives chronic low-grade inflammation, and propagates senescence to neighboring cells. The accumulation of senescent cells in tissues is now considered a primary cause — not merely a correlate — of aging and age-related disease. Senolytics are compounds that selectively eliminate senescent cells by exploiting their survival vulnerabilities. The dasatinib + quercetin (D+Q) combination was developed at the Mayo Clinic as the first senolytic protocol and published to immediate scientific impact in 2015. The rationale: dasatinib (a tyrosine kinase inhibitor approved for leukemia) targets pro-survival BCR-ABL and Src pathways overexpressed in senescent cells; quercetin (a plant flavonoid) inhibits PI3K/Akt survival signaling. Together, they hit complementary anti-apoptotic networks uniquely upregulated in senescent cells, while leaving normal cells relatively unaffected. The critical human evidence: the first published human senolytic trial (PMID 31542391) tested D 100mg + Q 1000mg × 3 consecutive days in patients with idiopathic pulmonary fibrosis. Results were striking — a 35% reduction in p16INK4a-positive senescent cells in adipose tissue biopsies, with concurrent reductions in circulating IL-1α and IL-6. Physical function improved significantly. Preclinical evidence now spans 40+ age-related conditions across cardiovascular disease, neurodegeneration, metabolic dysfunction, and musculoskeletal decline (PMC7790861). The standard senolytic protocol uses intermittent pulse dosing — 2 to 3 consecutive days per month — rather than chronic daily dosing. This aligns with the biological rationale: senescent cells accumulate over weeks to months, and clearance events followed by recovery periods may be more effective than continuous low-level exposure. Dasatinib requires prescription access and carries significant interaction risks; quercetin is OTC. The combination should not be attempted without physician oversight and appropriate baseline assessment.

Taurine has been dismissed for years as a minor amino acid found in energy drinks — an afterthought compared to branched-chain amino acids or creatine. The publication of a landmark 2023 Science paper changed that calculus permanently. The study by Yadav et al. (DOI: 10.1126/science.abn9257) demonstrated that taurine levels decline significantly with age across worms, mice, and humans; that supplementing taurine reversed this decline; and that taurine-supplemented mice lived 10–12% longer (12% in females, 10% in males) with compressible morbidity — more time in health, not just extended decline. The mechanism is multifactorial in ways that impress longevity biologists. Taurine supplementation in aged animals reversed increases in DNA damage markers, restored telomerase activity (addressing telomere attrition), improved mitochondrial membrane potential (addressing mitochondrial dysfunction), reduced the senescent cell burden (addressing cellular senescence), and decreased levels of inflammatory cytokines. This is a compound addressing at least four major aging hallmarks through what appears to be primarily a depletion-and-restoration dynamic rather than an artificial pharmacological override. The human relevance is reinforced by the age-related depletion data. Blood taurine levels in 60-year-old humans are approximately 80% lower than in 5-year-olds. A 3-gram/day supplementation protocol raised taurine to levels comparable to younger individuals in human participants included in the study. Taurine is produced endogenously from methionine and cysteine but production declines with age; dietary sources include meat and seafood. Taurine's safety profile is exceptional — it is one of the most abundant amino acids in the human body, present in breast milk, and has been consumed in multi-gram doses by billions of people in energy drinks without documented serious adverse effects at typical doses. For biohackers, the compound represents an unusually clean risk-benefit profile: the downside is minimal, the mechanism is scientifically grounded, and the 2023 Science publication is among the most rigorous longevity evidence published for any accessible compound. Typical longevity dosing is 2–6 grams/day, widely available OTC at low cost.

Alpha-ketoglutarate (AKG, also known as 2-oxoglutarate) is a key metabolite in the tricarboxylic acid (TCA/Krebs) cycle — the central hub of cellular energy metabolism. Its longevity credentials extend well beyond simple energy production. AKG is a required cofactor for ten-eleven translocation (TET) enzymes and Jumonji-domain histone demethylases that regulate DNA methylation and histone modification patterns — the epigenetic machinery central to the hallmark of epigenetic alterations. As AKG levels decline with age, epigenetic drift accelerates. Additionally, AKG inhibits ATP synthase and activates AMPK (mimicking aspects of caloric restriction), inhibits mTOR signaling (overlapping with rapamycin's mechanism through a distinct pathway), and serves as a direct precursor for glutamate and glutathione (the primary intracellular antioxidant). This positions AKG at the convergence of at least five aging pathways: epigenetic regulation, nutrient sensing (mTOR/AMPK), mitochondrial function, oxidative stress, and proteostasis. The human evidence is anchored by the Rejuvant trial (PMC8660611), which tested a calcium alpha-ketoglutarate formulation in 42 participants over approximately seven months. Using the Horvath DNA methylation clock (an epigenetic measure of biological age) as the primary endpoint, the trial found a mean biological age reduction of approximately 8 years. The confidence intervals were wide given the small sample size, but the direction and magnitude of the signal attracted immediate attention from the aging research community. A follow-up RCT is currently registered on ClinicalTrials.gov (NCT07114536), with larger sample size and pre-registered endpoints that will substantially clarify the compound's efficacy. AKG is available OTC as calcium AKG (Ca-AKG) — typically dosed at 1–2 grams/day — at a cost of approximately $50–100/month for quality formulations. It is well-tolerated with minimal reported side effects at standard doses, and the mechanistic rationale for its epigenetic effects is grounded in basic biochemistry.

Fisetin (3,3',4',7-tetrahydroxyflavone) is a plant polyphenol found in strawberries, apples, onions, and cucumbers — concentrated particularly in strawberries where it reaches approximately 160 micrograms per gram of fruit. Despite its humble dietary origins, fisetin has emerged as one of the most potent senolytic compounds identified, offering a safety profile that makes it uniquely suitable for broader biohacker adoption compared to the prescription-only dasatinib. The landmark preclinical evidence comes from Buck Institute research (PMC12341784) demonstrating that fisetin achieves approximately 68% clearance of senescent cells in aged mouse tissues — a magnitude comparable to genetic clearance methods that use inducible suicide genes to selectively eliminate p16- or p21-expressing cells. This comparison is significant: genetic clearance is considered the 'ground truth' of senolytic efficacy, and fisetin reaching equivalent clearance via a small-molecule flavonoid represents a remarkable result. Fisetin's senolytic mechanism operates through inhibition of pro-survival pathways in senescent cells — specifically the PI3K/Akt/mTOR axis and Bcl-2 family proteins — while also demonstrating anti-inflammatory, antioxidant, and neuroprotective activities. Mayo Clinic researchers have classified it as one of the most potent natural senolytics identified in systematic screening of plant compounds. Human clinical data for fisetin specifically remains limited — the most relevant trial examined it in COVID-19 elderly patients with favorable tolerability — but its safety profile in preclinical and early human studies is described universally as exceptional. A human senolytic efficacy trial (AFFIRM-LITE) has examined fisetin in older adults, with tolerability confirmed and efficacy signals under analysis. Typical senolytic protocols use fisetin at 500–1500mg/day for 2–3 consecutive days per month, mirroring the pulse-dosing rationale used for D+Q. Bioavailability is enhanced significantly by taking fisetin with fat-containing food. Formulations with enhanced bioavailability (liposomal or emulsified) are preferred given the compound's poor water solubility. Cost is modest — $30–60/month for quality pulse-dose protocols.

Spermidine is a naturally occurring polyamine found throughout human cells and in concentrated amounts in wheat germ, aged cheese, soy products, and mushrooms. Its longevity credentials center on autophagy induction — the cellular self-cleaning process that degrades damaged proteins, dysfunctional organelles, and intracellular pathogens. Autophagy declines with age, and its declining activity is now recognized as a primary driver of the proteostasis failure and mitochondrial dysfunction that characterize aged tissues. Spermidine's autophagy-inducing mechanism is distinct from caloric restriction and mTOR inhibition: it works by inhibiting acetyltransferases that would otherwise suppress the autophagy regulatory network, and by stabilizing microtubule-associated protein 1 light chain 3 (LC3), a central component of autophagosome formation. This mechanistic independence from mTOR/AMPK pathways means spermidine may complement metformin, rapamycin, or AKG in a stack without significant overlap. The human evidence base took a meaningful step forward with the SmartAge trial (PMC9136623) — a 12-month double-blind RCT testing 0.9mg/day of spermidine from wheat germ extract in older adults with subjective cognitive decline. Results: the intervention was safe and well-tolerated with no significant adverse events. Cognitive outcomes showed a non-significant trend toward improvement versus placebo, but the trial was not powered to detect small effects. An earlier safety study (PMC5807086) confirmed safety in older adults at comparable doses. Longevity researchers note that the SmartAge dose (0.9mg/day) may be subtherapeutic for maximal autophagy induction. Epidemiological data correlating higher dietary spermidine intake with reduced mortality has driven interest in higher-dose supplementation protocols, with some practitioners using 5–15mg/day of purified spermidine — doses significantly higher than the SmartAge trial. The wheat germ source used in SmartAge provides a food-derived, well-tolerated delivery vehicle. Spermidine levels in blood decline with age, supporting a depletion-and-restoration rationale analogous to taurine.

Berberine is a yellow isoquinoline alkaloid found in several plants including Berberis vulgaris (barberry), goldenseal, goldthread, and Oregon grape. It has been used in traditional Chinese and Ayurvedic medicine for millennia — primarily for its antimicrobial and glucose-regulating properties. In the context of modern longevity science, berberine's significance lies in its pharmacological similarity to metformin: it activates AMP-activated protein kinase (AMPK) through inhibition of mitochondrial Complex I, producing a nearly identical downstream cascade. This mechanism — dubbed 'nature's metformin' by researchers and popularized in longevity circles since a 2021 analysis in Ageing Research Reviews — produces the same core effects: inhibition of mTOR signaling, reduction of IGF-1, enhanced autophagy, improved insulin sensitivity, reduced gluconeogenesis, and lower circulating glucose and lipid levels. A 2008 RCT found berberine matched metformin's glycemic control in type 2 diabetes patients at 1500mg/day — a comparison that entered the popular consciousness as evidence of bioequivalence. Whether that equivalence extends to metformin's broader geroprotective effects remains an active research question. Berberine offers two significant advantages over metformin for the biohacker context: OTC availability (no prescription required in most jurisdictions) and substantially more accessible pricing. Quality berberine HCl supplementation at 500mg three times daily costs approximately $20–40/month. Dihydroberberine (DHB), a reduced form with higher oral bioavailability and fewer GI side effects, is also available OTC at somewhat higher cost. Limitations worth acknowledging: berberine's human longevity data lags behind metformin by decades, there is no TAME-equivalent trial, and its bioavailability from standard HCl salt formulations is poor (~5%) due to first-pass metabolism and efflux transport. Taking berberine with a meal containing fat and cycling its use (two weeks on, one week off) are common strategies to maintain sensitivity. Interactions with CYP3A4-metabolized medications require attention.

Epigenetic reprogramming represents not a supplement but a biological intervention category that is transitioning from theoretical breakthrough to clinical trial reality. The foundation is Shinya Yamanaka's 2006 Nobel Prize-winning discovery that four transcription factors (Oct4, Sox2, Klf4, c-Myc — collectively OSKM) can reprogram adult cells back to an induced pluripotent stem cell (iPSC) state. The challenge for longevity applications: full reprogramming erases cellular identity and risks teratoma formation. The paradigm shift came with partial reprogramming: brief, transient expression of OSKM (or the safer OSK subset, excluding the oncogenic c-Myc) that resets the epigenetic clock without inducing full pluripotency. David Sinclair's lab at Harvard demonstrated in 2020 that OSK expression in retinal ganglion cells reversed epigenetic age and restored visual function in aged and damaged mice — the first demonstration that mammalian tissue aging could be reversed in vivo. Subsequent work has extended this to muscle, kidney, brain, and liver tissues. Preclinical evidence published in 2025 (PMC12610414) demonstrates that partial OSKM reprogramming resets the epigenome without inducing pluripotency across multiple tissue types, with gene expression profiles reverting to youthful patterns. The mechanistic target is epigenetic drift — the progressive, stochastic accumulation of methylation errors at CpG sites that constitutes one of the most robustly measured aging hallmarks (the DNA methylation clocks developed by Horvath and others directly measure this). The clinical translation is accelerating. Life Biosciences has been developing ER-100, a partial epigenetic reprogramming therapeutic targeting clinic entry in Q1 2026. Altos Labs (backed by over $3 billion in funding) is actively researching mesenchymal drift reversal and whole-body epigenetic reprogramming approaches. These are not consumer supplements — they are sophisticated gene therapy and small-molecule approaches requiring clinical delivery. For the biohacker community, the immediate relevance is conceptual and forward-looking: epigenetic reprogramming is the mechanism that upstream interventions like AKG, NMN, and senolytics are attempting to influence indirectly. The compounds that preserve epigenetic fidelity or reduce drift rate — AKG as TET cofactor, NAD+ for PARP-mediated repair, senolytics for SASP-driven epigenetic disruption — can be understood as supporting the substrate that reprogramming seeks to reset.